CTLLAB
Clinitech Laboratory financials
- Market cap
- ₹9 Cr
Quarterly results
Q4 FY26: revenue up 32.0%, net profit down 60.0% against the same quarter last year.
| Line item | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 3 | 3 | 4 | 4 | 5 +66% | 4 +32% |
| EBITDA | 0 | 1 | 1 | 0 | 1 +93% | 0 −38% |
| Net profit | 0 | 0 | 0 | 0 | 0 +329% | 0 −60% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −33.1% 1Y
1Y: ₹52.5 on 29 Aug 2025 → ₹35.1. High ₹54.5 (8 Sept 2025), low ₹31.72 (28 Jan 2026).
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| Reserves | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹7 Cr | ₹7 Cr |
| Borrowings | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Other liabilities | ₹1 Cr | ₹1 Cr | ₹3 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr |
| Total liabilities | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹11 Cr | ₹11 Cr |
| Fixed assets | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
| Capital work in progress | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹8 Cr | ₹8 Cr |
| Total assets | ₹3 Cr | ₹4 Cr | ₹6 Cr | ₹6 Cr | ₹11 Cr | ₹11 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Mar 2026
Since Mar 2025, promoters added +2.63 pp while the public trimmed −2.62 pp. The shareholder count shrank 2% to 297.
- Promoters
- 64.2%
- FIIs
- 0.3%
- Public
- 35.5%
Since Mar 2025
- Promoters +2.63 pp
- Public −2.62 pp
- FIIs 0.00 pp
How it drifted, 4 quarters
Over this window promoters went from 61.6% to 64.2% — +2.6 pp.
Ownership split by quarter, oldest first. Sep '24: Promoters 61.6%, FIIs 0.3%, Public 38.1%.Mar '25: Promoters 61.6%, FIIs 0.3%, Public 38.1%.Sep '25: Promoters 62.4%, FIIs 0.3%, Public 37.3%.Mar '26: Promoters 64.2%, FIIs 0.3%, Public 35.5%.
Who bought this quarter
since Sep 2025
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Shirish Nanubhai Patel newly disclosed 1.58% held
- Jagdish Umakant Nayak +1.27 pp 31.66% held
- Siddhesh Nayak newly disclosed 0.53% held
The same filing shows 0 holders trimming and 2 off the list — both are in the register beside this.
Who is on the register
Named in the Mar 2026 filing
Every holder of Clinitech Laboratory Limited above SEBI's 1% disclosure line, and what changed since Sep 2025.
| Holder | Stake | Change |
|---|---|---|
| Jagdish Umakant Nayak | 31.66% | +1.27 pp |
| Jyoti Jagdish Nayak | 29.57% | unchanged |
| Santosh Gopalkrishna Kudva | 5.84% | unchanged |
| Krisha V Talreja | 3.10% | unchanged |
| Siddhesh Anant Nayak | 2.43% | unchanged |
| Ajit Sakharam Kandar | 2.24% | unchanged |
| Shirish Nanubhai Patel | 1.58% | newly disclosed |
| Siddhesh Nayak | 0.53% | newly disclosed |
| Ananya Jagdish Nayak | 0.00% | unchanged |
| Eshwari Anant Nayak | 0.00% | unchanged |
| Ashutosh Jagdish Nayak | 0.00% | unchanged |
| Anant Umakant Nayak | 0.00% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Learn to analyse Clinitech Laboratory Limited
Guides on how to read this kind of business and the numbers that matter.